Drug
ICP-192
ICP-192 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_2
3
75%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Other(2)
Detailed Status
Recruiting2
unknown2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
recruiting250%
unknown250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_2
An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
NCT04492293
recruitingphase_2
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05678270
unknownphase_2
A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
NCT05372120
unknownphase_1
Clinical Study of ICP-192 in Solid Tumors Patients
NCT03758664
Clinical Trials (4)
Showing 4 of 4 trials
NCT04492293Phase 2
An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
NCT05678270Phase 2
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05372120Phase 2
A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
NCT03758664Phase 1
Clinical Study of ICP-192 in Solid Tumors Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4